BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 30655151)

  • 1. Efficacy of Direct-acting Antivirals to Improve Clinical Condition, Fibrosis, and Liver Function in Liver Transplant Recipients Infected by Hepatitis C.
    Garcia-Pajares F; Tejedor-Tejada J; Torres-Yuste R; Almohalla-Alvárez C; Sánchez-Ocaña R; Peñas-Herrero I; Cimavilla-Román M; de Benito-Sanz M; Sánchez-Martín F; Sánchez-Antolín G
    Transplant Proc; 2019; 51(1):74-76. PubMed ID: 30655151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort.
    Sanchez Antolin G; Testillano M; Pascasio JM; Narvaez Rodriguez I; Prieto M; Otero A; Herrero JI; Londoño M; Fernandez Vazquez I; Castells L;
    Transplant Proc; 2016 Nov; 48(9):3013-3016. PubMed ID: 27932134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
    Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
    Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
    Ji F; Yeo YH; Wei MT; Ogawa E; Enomoto M; Lee DH; Iio E; Lubel J; Wang W; Wei B; Ide T; Preda CM; Conti F; Minami T; Bielen R; Sezaki H; Barone M; Kolly P; Chu PS; Virlogeux V; Eurich D; Henry L; Bass MB; Kanai T; Dang S; Li Z; Dufour JF; Zoulim F; Andreone P; Cheung RC; Tanaka Y; Furusyo N; Toyoda H; Tamori A; Nguyen MH
    J Hepatol; 2019 Sep; 71(3):473-485. PubMed ID: 31096005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients.
    Cholongitas E; Pipili C; Papatheodoridis G
    World J Gastroenterol; 2015 Aug; 21(32):9526-33. PubMed ID: 26327760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort.
    Alem SA; Said M; Anwar I; Abdellatif Z; Elbaz T; Eletreby R; AbouElKhair M; El-Serafy M; Mogawer S; El-Amir M; El-Shazly M; Hosny A; Yosry A
    J Med Virol; 2018 Sep; 90(9):1508-1515. PubMed ID: 29718546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histological assessment of the liver explant in transplanted hepatitis C virus patients achieving sustained virological response with direct-acting antiviral agents.
    Putra J; Schiano TD; Fiel MI
    Histopathology; 2018 May; 72(6):990-996. PubMed ID: 29235144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
    García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
    Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated Care for the Use of Direct-acting Antivirals in Patients With Chronic Hepatitis C and Substance Use Disorder.
    Trabut JB; Barrault C; Charlot H; Carmona D; Bourdel A; Benslimane M; François M; Kini-Matondo W; Causse R; Roudot-Thoraval F; Hézode C
    J Addict Med; 2018; 12(5):346-352. PubMed ID: 29702515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
    Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
    Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
    Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
    Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C.
    Raschzok N; Schott E; Reutzel-Selke A; Damrah I; Gül-Klein S; Strücker B; Sauer IM; Pratschke J; Eurich D; Stockmann M
    Transpl Infect Dis; 2016 Dec; 18(6):896-903. PubMed ID: 27632190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The elderly and direct antiviral agents: Constraint or challenge?
    Fabrizio C; Saracino A; Scudeller L; Milano E; Dell'Acqua R; Bruno G; Lo Caputo S; Monno L; Milella M; Angarano G
    Dig Liver Dis; 2017 Sep; 49(9):1036-1042. PubMed ID: 28651903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease.
    Sinakos E; Kountouras D; Koskinas J; Zachou K; Karatapanis S; Triantos C; Vassiliadis T; Goulis I; Kourakli A; Vlachaki E; Toli B; Tampaki M; Arvaniti P; Tsiaoussis G; Bellou A; Kattamis A; Maragkos K; Petropoulou F; Dalekos GN; Akriviadis E; Papatheodoridis GV
    Br J Haematol; 2017 Jul; 178(1):130-136. PubMed ID: 28439915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.
    Pillai AA; Wedd J; Norvell JP; Parekh S; Cheng N; Young N; Spivey JR; Ford R
    Am J Gastroenterol; 2016 Feb; 111(2):250-60. PubMed ID: 26832650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis.
    Martini S; Sacco M; Strona S; Arese D; Tandoi F; Dell Olio D; Stradella D; Cocchis D; Mirabella S; Rizza G; Magistroni P; Moschini P; Ottobrelli A; Amoroso A; Rizzetto M; Salizzoni M; Saracco GM; Romagnoli R
    Liver Int; 2017 Jan; 37(1):62-70. PubMed ID: 27344058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-emptive Treatment of HCV after Living Donor Liver Transplantation with Direct-Acting Antiviral Agents.
    Jung J; Kwon JH; Song GW; Tak EY; Kirchner VA; Lee SG
    J Gastrointest Surg; 2018 Aug; 22(8):1334-1342. PubMed ID: 29679347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.
    Pillai AA; Maheshwari R; Vora R; Norvell JP; Ford R; Parekh S; Cheng N; Patel A; Young N; Spivey JR; Mgbemena O; Wedd JP
    Aliment Pharmacol Ther; 2017 Jun; 45(11):1427-1432. PubMed ID: 28382751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.
    Werner CR; Schwarz JM; Egetemeyr DP; Beck R; Malek NP; Lauer UM; Berg CP
    World J Gastroenterol; 2016 Sep; 22(35):8050-9. PubMed ID: 27672299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.